The use of animals in drug manufacturing has always been a necessary evil, but new developments in the field of genetic engineering could well mark the end of the practice in some fields.
Gaucher disease – a condition resulting from the lack of a particular enzyme – is traditionally treated with drugs derived from hamster cells. Now, however, Israeli scientists from biotech firm Protalix Biotherapeutics, have discovered a way to grow the required enzymes in carrot cells instead, by inserting specific genes into them.
Patients that received the ‘bio-pharmed’ version of the drug reportedly showed the same levels of improvement as those given the treatment derived from hamster cells.
The US Federal Drug Administration (FDA) has given its approval for the plant-derived treatment, potentially the marking the beginning of the end of genetically modified livestock in drug factories.